For the year ending 2025-12-31, NAUT had -$15,258K decrease in cash & cash equivalents over the period. -$51,973K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -59,001 |
| Stock-based compensation | 6,844 |
| Amortization of operating lease right-of-use assets | 4,712 |
| Depreciation | 1,753 |
| In-process research and development | 0 |
| Amortization (accretion) of premiums (discounts) on securities, net | 1,420 |
| Prepaid expenses and other assets | -544 |
| Accounts payable | -69 |
| Accrued expenses and other liabilities | 629 |
| Operating lease liabilities | -4,688 |
| Net cash used in operating activities | -50,696 |
| Proceeds from maturities of securities | 108,991 |
| Purchases of securities | 72,490 |
| Purchases of property and equipment | 1,277 |
| Cash paid in connection with asset acquisition | 0 |
| Net cash provided by investing activities | 35,224 |
| Proceeds from exercise of stock options | 58 |
| Proceeds from issuance of common stock under employee stock purchase plan | 156 |
| Net cash provided by financing activities | 214 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | -15,258 |
| Cash, cash equivalents and restricted cash at beginning of period | 28,648 |
| Cash, cash equivalents and restricted cash at end of period | 13,390 |
Nautilus Biotechnology, Inc. (NAUT)
Nautilus Biotechnology, Inc. (NAUT)